BACKGROUND: Since the beginning of the program of immunization of children against measles, mumps and rubella (MMR) in 1987, various outbreaks of mumps have occurred in Switzerland, with a significant proportion of cases in immunized children. Previous studies have suggested a possible lack of efficacy of the Rubini vaccine strain, which has been much used in this country. METHODS: Incidence study of secondary cases of mumps in the schools of Geneva, between March 18th and June 30th 1994. STUDY POPULATION: During the study period, mumps outbreaks have been observed in 10 school classes. After exclusion of the 10 primary cases, the study population comprised 195 children aged 4 to 12 years. RESULTS: Raw estimation of vaccine efficacy against mumps was 72.5%. Whereas both the Urabe and Jeryl-Lynn strains showed a significant efficacy, the Rubini strain didn't show any significant protective effect. After adjustment by Poisson regressions for the confounding effect of age, efficacy rates and 95% confidence limits were 75.8% (35.6%, 90.9%) for Urabe; 64.7% (10.6%, 86.0%) for Jeryl-Lynn; and 12.4% (-102%, 62.1%) für Rubini. CONCLUSION: This study didn't show any protective effect of the Rubini vaccine strain. Furthermore, it demonstrated a statistically significant protective effect of the Urabe and Jeryl-Lynn strains, compared to the Rubini strains. In this conditions the use of the Rubini strain should be restricted to situations of confirmed contra-indications to the other vaccinal strains, as long as its protective efficacy is not clearly demonstrated.
BACKGROUND: Since the beginning of the program of immunization of children against measles, mumps and rubella (MMR) in 1987, various outbreaks of mumps have occurred in Switzerland, with a significant proportion of cases in immunized children. Previous studies have suggested a possible lack of efficacy of the Rubini vaccine strain, which has been much used in this country. METHODS: Incidence study of secondary cases of mumps in the schools of Geneva, between March 18th and June 30th 1994. STUDY POPULATION: During the study period, mumps outbreaks have been observed in 10 school classes. After exclusion of the 10 primary cases, the study population comprised 195 children aged 4 to 12 years. RESULTS: Raw estimation of vaccine efficacy against mumps was 72.5%. Whereas both the Urabe and Jeryl-Lynn strains showed a significant efficacy, the Rubini strain didn't show any significant protective effect. After adjustment by Poisson regressions for the confounding effect of age, efficacy rates and 95% confidence limits were 75.8% (35.6%, 90.9%) for Urabe; 64.7% (10.6%, 86.0%) for Jeryl-Lynn; and 12.4% (-102%, 62.1%) für Rubini. CONCLUSION: This study didn't show any protective effect of the Rubini vaccine strain. Furthermore, it demonstrated a statistically significant protective effect of the Urabe and Jeryl-Lynn strains, compared to the Rubini strains. In this conditions the use of the Rubini strain should be restricted to situations of confirmed contra-indications to the other vaccinal strains, as long as its protective efficacy is not clearly demonstrated.
Authors: P A Briss; L J Fehrs; R A Parker; P F Wright; E C Sannella; R H Hutcheson; W Schaffner Journal: J Infect Dis Date: 1994-01 Impact factor: 5.226
Authors: J Eriksen; I Davidkin; G Kafatos; N Andrews; C Barbara; D Cohen; A Duks; A Griskevicius; K Johansen; K Bartha; B Kriz; G Mitis; J Mossong; A Nardone; D O'Flanagan; F DE Ory; A Pistol; H Theeten; K Prosenc; M Slacikova; R Pebody Journal: Epidemiol Infect Date: 2012-06-12 Impact factor: 4.434